Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
- 25 January 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 63 (3), 731-737
- https://doi.org/10.1007/s10620-018-4935-5
Abstract
Histological remission represents a target distinct from endoscopic healing in ulcerative colitis (UC) and seems a better predictor of clinical outcomes.Keywords
This publication has 39 references indexed in Scilit:
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- Oral budesonide for induction of remission in ulcerative colitisPublished by Wiley ,2010
- Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left‐sided ulcerative colitisAlimentary Pharmacology & Therapeutics, 2010
- Severity of Inflammation as a Predictor of Colectomy in Patients With Chronic Ulcerative ColitisDiseases of the Colon & Rectum, 2009
- Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trialGut, 2008
- Histologic Inflammation Is a Risk Factor for Progression to Colorectal Neoplasia in Ulcerative Colitis: A Cohort StudyGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- A reproducible grading scale for histological assessment of inflammation in ulcerative colitisGut, 2000
- Microscopic activity in ulcerative colitis: what does it mean?Gut, 1991